Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Abiraterone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    146 result(s) found for: Abiraterone. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2020-000346-33 Sponsor Protocol Number: D361BC00001 Start Date*: 2020-07-20
    Sponsor Name:AstraZeneca AB
    Full Title: Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing Efficacy and Safety of Capivasertib+Abiraterone Versus Placebo+Abiraterone as Treatment for Patients with DeNovo Metastatic Ho...
    Medical condition: Metastatic Hormone-Sensitive Prostate Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Ongoing) BG (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) SK (Ongoing) BE (Ongoing) PL (Ongoing) DE (Ongoing) FR (Ongoing) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003189-29 Sponsor Protocol Number: ONCO-01-2017 Start Date*: 2018-02-09
    Sponsor Name:L'Institut Mutualiste Montsouris
    Full Title: A phase II/III multicentric randomized trial, compared abiraterone + dexamethasone versus standard abiraterone + prednisone in patients resistant-castration in metastatic prostate cancer
    Medical condition: Metastatic castration resistant prostate cancer patients under abiraterone + prednisone with exclusive biological progression (PSA progression on the PSAWG3 criteria)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003485-40 Sponsor Protocol Number: CCR5163 Start Date*: 2020-10-01
    Sponsor Name:The Institute of Cancer Research
    Full Title: ACTION: Phase I/II Trial of Abiraterone Acetate in Combination with Tildrakizumab (anti-IL23 targeting monoclonal antibody) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Medical condition: Metastatic castration resistant prostate cancer
    Disease:
    Population Age: Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-005243-28 Sponsor Protocol Number: 212082PCR3010 Start Date*: 2012-03-14
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (PCR)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) HU (Prematurely Ended) ES (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003226-25 Sponsor Protocol Number: Abifood01 Start Date*: 2013-07-12
    Sponsor Name:Fundacion Publica Andaluza para la Gestion de la Investigacion en Salud de Sevilla
    Full Title: Phase I, randomized, open design trial to evaluate the effect of food (fasting, fat meal and standard meal) on the pharmacokinetics of abiraterone acetate at reduced doses, compared with convention...
    Medical condition: metastatic prostatic cancer after castration-resistant progression to docetaxel
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10036947 Prostatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002210-22 Sponsor Protocol Number: COU-AA-003-EXT Start Date*: 2008-09-25
    Sponsor Name:Janssen Oncology, Inc.
    Full Title: An Extended Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy and Completed Clinical Study COU-AA...
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004118-16 Sponsor Protocol Number: MK-7339-010 Start Date*: 2019-04-15
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castrationresistant Prostate Cancer (mCRPC...
    Medical condition: Metastatic Castration resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) ES (Completed) IE (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002014-13 Sponsor Protocol Number: MAdCaP2013 Start Date*: 2014-03-05
    Sponsor Name:NHS greater Glasgow and Clyde [...]
    1. NHS greater Glasgow and Clyde
    2. Glasgow University
    Full Title: A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 / idasanutlin in patients with metastatic castration resistant prostate cancer who have not previously receiv...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-004429-17 Sponsor Protocol Number: CO39303 Start Date*: 2018-09-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE, RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/...
    Medical condition: Metastatic Castrate-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NO (Completed) PT (Completed) DE (Completed) DK (Completed) HU (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) IE (Completed) BE (Completed) ES (Ongoing) GR (Ongoing) PL (Completed) FR (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002011-10 Sponsor Protocol Number: D081SC00001 Start Date*: 2018-11-02
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration...
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) CZ (Ongoing) SK (Trial now transitioned) NL (Ongoing) FR (Trial now transitioned) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004126-10 Sponsor Protocol Number: GO27983 Start Date*: 2012-04-19
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE Ib/II STUDY OF GDC-0068 OR GDC-0980 WITH ABIRATERONE ACETATE VERSUS ABIRATERONE ACETATE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTH...
    Medical condition: Castration-Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GR (Completed) CZ (Completed) ES (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003520-37 Sponsor Protocol Number: D081DC00008 Start Date*: 2014-02-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatmen...
    Medical condition: metastatic castrate-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) CZ (Completed) ES (Completed) IT (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002021-28 Sponsor Protocol Number: PLX124-04 Start Date*: 2020-09-24
    Sponsor Name:Plexxikon Inc.
    Full Title: A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects wi...
    Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001166-13 Sponsor Protocol Number: COU-AA-001 Start Date*: 2005-09-21
    Sponsor Name:Cougar Biotechnology, Inc
    Full Title: A Phase I/II Open Label Study of the 17α-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy
    Medical condition: Hormone refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.0 10062904
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001574-28 Sponsor Protocol Number: AT13387-04 Start Date*: 2012-10-09
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Phase 2 Study of Hsp90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
    Medical condition: Castration-Resistant Prostate Cancer (CRPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-002209-25 Sponsor Protocol Number: 67652000PCR3002 Start Date*: 2020-10-12
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Parti...
    Medical condition: Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) DK (Trial now transitioned) PL (Trial now transitioned) DE (Ongoing) PT (Ongoing) BG (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000285-10 Sponsor Protocol Number: CCS1477-01 Start Date*: 2021-07-26
    Sponsor Name:CellCentric Ltd
    Full Title: An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination, in patients with advanced solid/metastatic tumours.
    Medical condition: Metastatic Castrate Resistant Prostate Cancer (mCRPC) and other advanced cancers with solid tumours.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2012-002250-23 Sponsor Protocol Number: CBEZ235D2101 Start Date*: 2012-10-17
    Sponsor Name:Novartis Farmaceutica S.A.
    Full Title: Phase Ib dose finding study of abiraterone acetate plus BEZ235 or BKM120 in patients with castration-resistant prostate cancer
    Medical condition: patients with castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2016-000300-28 Sponsor Protocol Number: D081DC00007 Start Date*: 2017-02-24
    Sponsor Name:AstraZeneca
    Full Title: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate C...
    Medical condition: Metastatic castration-resistant prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076506 Castration-resistant prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: SE (Completed) DK (Completed) NO (Completed) ES (Completed) AT (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003364-12 Sponsor Protocol Number: 64091742PCR3001 Start Date*: 2019-04-17
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects ...
    Medical condition: Metastatic Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) FR (Trial now transitioned) NL (Completed) CZ (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:26:29 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA